By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

D-Pharm Ltd. 

Kiryat Weizmann Science Park, Bldg. 7
P.O. Box 2313
Rehovot    76123  Israel
Phone: Fax:


SEARCH JOBS








Company News
D-Pharm Ltd.’s DP-b99 Prevents Abnormal Neuronal Plasticity And Pathological Brain Reorganization. 6/12/2014 9:20:21 AM
D-Pharm Ltd.'s DP-b99 Prevents Abnormal Neuronal Plasticity And Pathological Brain Reorganization 6/12/2014 7:19:23 AM
D-Pharm Ltd.'s Anti-Epileptic Drug DP-VPA Is Granted Fast Track Status By The Chinese Food And Drug Administration (CFDA) 6/9/2014 11:32:40 AM
D-Pharm Ltd. Reports Completion Of The Second Dose Tier In Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 6/2/2014 10:49:59 AM
D-Pharm Ltd. Reports The Successful Interim Analysis Of Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 3/4/2014 7:13:07 AM
D-Pharm Ltd. Completes Recruitment Of Patients Into The First Dosage Tier Of Its Phase 2 Study With THR-18 In Acute Stroke Patients Treated With tPA. 1/21/2014 10:43:10 AM
D-Pharm Ltd. Announces Recruitment Of The First Patient Into Its Phase 2 Clinical Trial With DP-B99 In Acute High-Risk Pancreatitis 1/14/2014 9:58:59 AM
D-Pharm Ltd. Reports Enrollment Of First Patient Into Phase 2 Study Of THR-18 In Stroke Patients Treated With Tissue Plasminogen Activator (tPA) 1/2/2014 9:03:53 AM
D-Pharm Ltd. Granted Patent in US and China for its Phase 2 Product THR-18 10/30/2013 10:56:41 AM
D-Pharm Ltd. Commences Phase 2 Study With THR-18 in Stroke Patients Treated With Tissue Plasminogen Activator (tPA) 10/16/2013 6:55:14 AM
12345
//-->